Solid Biosciences Inc. (SLDB)
NASDAQ: SLDBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SLDB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $697.57M
- EPS (TTM)
- -$1.76
- Dividend yield
- None
- 52-week range
- 4.65 – 11.45
- Day range
- 6.20 – 6.53
- Volume / Avg
- 1.56M / 1.30M
- Beta
- —
- Shares outstanding
- 111.61M
52-week range
SLDB stock today
Solid Biosciences (SLDB) closed at $6.25 on Nov 20, down 2.95% (-$0.19), versus the S&P 500's 3.70% decline. Shares are 45.4% below their 52-week high of $11.45, set on Jul 6, 2026 and 34.4% above the 52-week low of $4.65, in the middle of the past year's range. SLDB is up 10.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 33.0%.
Solid Biosciences has posted a net loss over the last twelve months (EPS of -$1.76), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Solid Biosciences
Company profileSolid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Alexander G. Cumbo
- Headquarters
- Charlestown, MA
- Employees
- 121
- IPO year
- 2018
- Website
- solidbio.com
Financial highlights
Full financialsSolid Biosciences reported a net loss of $174.3 million, compared with a loss of $124.7 million a year earlier. Diluted earnings per share came in at -$1.99.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $8.09M | $13.62M |
| Growth | — | — | — | -40.57% | — |
| Net income | $-174.32M | $-124.70M | $-96.02M | $-85.98M | $-72.19M |
| EPS (diluted) | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.14 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$18.71+199.36%
- Strong buy 5
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.36 vs $-0.37
- Surprise
- +2.70%
SLDB news
All SLDB news- Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceGlobeNewswire
- Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026GlobeNewswire
- UBS Initiates Coverage of Solid Biosciences at BuyNasdaq
Solid Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs SLDB |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs SLDB |
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs SLDB |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs SLDB |
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs SLDB |
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs SLDB |
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs SLDB |
| BBTXBambusa Therapeutics Inc. | 16.00 | +2.89% | $815.08M | vs SLDB |
Indexes, lists and sector
Solid Biosciences stock FAQ
What is Solid Biosciences's stock price today?
SLDB last traded at $6.25 as of Nov 20, 4:00 PM EST, down 2.95% on the day. Prices are delayed at least 15 minutes.
Does Solid Biosciences pay a dividend?
No. Solid Biosciences does not currently pay a regular cash dividend.
Who is Solid Biosciences's CEO?
Mr. Alexander G. Cumbo is the chief executive officer of Solid Biosciences Inc., which has about 121 employees.
Has SLDB ever split its stock?
Yes. The most recent SLDB stock split was a 1-for-15 split on Oct 28, 2022.
What is the SLDB 52-week high?
The 52-week high for SLDB is $11.45 and the 52-week low is $4.65. The stock is currently 45.4% below its high.